Explore the words cloud of the BrainDrain project. It provides you a very rough idea of what is the project "BrainDrain" about.
The following table provides information about the project.
|Coordinator Country||Finland [FI]|
|Total cost||2˙420˙429 €|
|EC max contribution||2˙420˙429 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-08-01 to 2022-07-31|
Take a look of project's partnership.
|1||HELSINGIN YLIOPISTO||FI (HELSINGIN YLIOPISTO)||coordinator||2˙420˙429.00|
In 2010, 800 billion Euros was spent on brain diseases in Europe and the cost is expected to increase due to the aging population. – Here I propose to exploit our new discovery for research to alleviate this disease burden. In work selected by Nature Medicine among the top 10 ”Notable Advances” and by Science as one of the 10 ”Breakthroughs of the year” 2015, we discovered a meningeal lymphatic vascular system that serves brain homeostasis. We want to reassess current concepts about cerebrovascular dynamics, fluid drainage and cellular trafficking in physiological conditions, in Alzheimer’s disease mouse models and in human postmortem tissues. First, we will study the development and properties of meningeal lymphatics and how they are sustained during aging. We then want to analyse the clearance of macromolecules and protein aggregates in Alzheimer’s disease in mice that lack the newly discovered meningeal lymphatic drainage system. We will study if growth factor-mediated expansion of lymphatic vessels alleviates the parenchymal accumulation of neurotoxic amyloid beta and pathogenesis of Alzheimer’s disease and brain damage after traumatic brain injury. We will further analyse the role of lymphangiogenic growth factors and lymphatic vessels in brain solute clearance, immune cell trafficking and in a mouse model of multiple sclerosis. The meningeal lymphatics could be involved in a number of neurodegenerative and neuroinflammatory diseases of considerable human and socioeconomic burden. Several of our previous concepts have already been translated to clinical development and we aim to develop proof-of-principle therapeutic concepts in this project. I feel that we are just now in a unique position to advance frontline European translational biomedical research in this suddenly emerging field, which has received great attention worldwide.
|year||authors and title||journal||last update|
Daniel J. Crona, Andrew D. Skol, Veli-Matti LeppÃ¤nen, Dylan M. Glubb, Amy S. Etheridge, Eleanor Hilliard, Carol E. PeÃ±a, Yuri K. Peterson, Nancy Klauber-DeMore, Kari K. Alitalo, Federico Innocenti
Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib
published pages: 231-241, ISSN: 0008-5472, DOI: 10.1158/0008-5472.can-18-1089
|Cancer Research 79/1||2020-03-24|
Ebba Brakenhielm, Kari Alitalo
Cardiac lymphatics in health and disease
published pages: 56-68, ISSN: 1759-5002, DOI: 10.1038/s41569-018-0087-8
|Nature Reviews Cardiology 16/1||2020-03-24|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BRAINDRAIN" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "BRAINDRAIN" are provided by the European Opendata Portal: CORDIS opendata.